Inhibikase Therapeutics, Inc. (IKT)
2.43
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 12:39
Inhibikase Therapeutics Total Liabilities (Quarterly) : 10.26M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.26M |
| March 31, 2026 | 5.712M |
| December 31, 2025 | 8.301M |
| September 30, 2025 | 6.696M |
| June 30, 2025 | 8.800M |
| March 31, 2025 | 8.551M |
| December 31, 2024 | 3.734M |
| September 30, 2024 | 4.908M |
| June 30, 2024 | 3.730M |
| March 31, 2024 | 4.291M |
| December 31, 2023 | 3.529M |
| September 30, 2023 | 2.863M |
| June 30, 2023 | 2.883M |
| March 31, 2023 | 2.842M |
| December 31, 2022 | 3.901M |
| September 30, 2022 | 3.445M |
| June 30, 2022 | 4.490M |
| March 31, 2022 | 4.380M |
| Date | Value |
|---|---|
| December 31, 2021 | 4.054M |
| September 30, 2021 | 2.708M |
| June 30, 2021 | 2.162M |
| March 31, 2021 | 3.838M |
| December 31, 2020 | 4.998M |
| September 30, 2020 | |
| June 30, 2020 | 5.197M |
| March 31, 2020 | 4.740M |
| December 31, 2019 | 4.528M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 3.624M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | 1.700M |
| December 31, 2017 | 1.726M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 163.59M |
| Shareholders Equity (Quarterly) | 153.33M |
| Current Ratio | 15.82 |
| Net Debt Paydown Yield | 0.01% |